Who are rAd-p53 gene's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): chemotherapy plus p53, Onasemnogene Abeparvovec-xioi, p53 gene with surgery, Onasemnogene Abeparvovec-brve, voretigene neparvovec-rzyl, p53 with chemotherapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rad-p53-gene.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

rAd-p53 gene — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

rAd-p53 gene (rAd-p53 gene) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gene therapy; oncolytic virus. Area: Oncology.

marketed Gene therapy; oncolytic virus p53 tumor suppressor gene Oncology Small molecule Live · refreshed every 30 min

Target snapshot

rAd-p53 gene (rAd-p53 gene) — Shenzhen SiBiono GeneTech Co.,Ltd. rAd-p53 is a recombinant adenovirus carrying the wild-type p53 tumor suppressor gene that restores p53 function in cancer cells to induce apoptosis and inhibit tumor growth.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
rAd-p53 gene TARGET	rAd-p53 gene	Shenzhen SiBiono GeneTech Co.,Ltd	marketed	Gene therapy; oncolytic virus	p53 tumor suppressor gene
chemotherapy plus p53	chemotherapy plus p53	Shenzhen SiBiono GeneTech Co.,Ltd	marketed	Combination chemotherapy with p53 gene therapy	p53 tumor suppressor protein
Onasemnogene Abeparvovec-xioi	Onasemnogene Abeparvovec-xioi	Novartis Gene Therapies	marketed	Gene therapy	SMN1 gene
p53 gene with surgery	p53 gene with surgery	Shenzhen SiBiono GeneTech Co.,Ltd	marketed	Gene therapy (p53 tumor suppressor)	p53 (tumor protein p53)
Onasemnogene Abeparvovec-brve	Onasemnogene Abeparvovec-brve	Novartis Pharmaceuticals	marketed	Gene Therapy	SMN1 gene
voretigene neparvovec-rzyl	voretigene neparvovec-rzyl	Spark Therapeutics, Inc.	marketed	Gene therapy	RPE65 gene
p53 with chemotherapy	p53 with chemotherapy	Shenzhen SiBiono GeneTech Co.,Ltd	marketed	Gene therapy; recombinant adenovirus vector	p53 (tumor suppressor protein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gene therapy; oncolytic virus class)

Shenzhen SiBiono GeneTech Co.,Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). rAd-p53 gene — Competitive Intelligence Brief. https://druglandscape.com/ci/rad-p53-gene. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing